VNRX (volition.com) רווח נקי למניה (EPS TTM)

The integration of Nu.Q into standard blood tests is driving the growth of VolitionRx Limited (VNRX) average annual revenue per user. While the high precision of epigenetic screening strengthens brand authority, R&D expenditures and a slow time-to-market for tests are creating financial pressure. This chart illustrates the profit response to business scaling, while -3.04 captures the current value of the indicator.

This indicator determines the portion of net income attributable to a single common share over a rolling year. The metric allows for an assessment of real capital generation efficiency by excluding the impact of the total issuance volume. For VolitionRx Limited (VNRX), the development of this figure depends directly on the commercialization of oncology tests and the hiring of US market experts. By analyzing the rolling 12-month net income per share, an investor can see the pace of business scaling. Steady growth of the line confirms the transition from scientific research to a profitable operating model.